Skip to main
PHVS
PHVS logo

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 0%
Buy 80%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris NV is a late-stage biopharmaceutical company focused on developing deucrictibant, an oral bradykinin B2 receptor antagonist, for the treatment and prevention of hereditary angioedema (HAE) attacks. The company is actively enrolling participants in a pivotal Phase 3 study, with the potential for further upside related to an ultra-orphan indication, enhancing the attractiveness of its asset given the estimated prevalence within the target population. The unique dual modes of treatment offered by deucrictibant create a distinctive position for Pharvaris in the HAE landscape, suggesting a strong scarcity value for its product.

Bears say

Pharvaris NV faces significant financial challenges that may hinder its ability to advance its drug development pipeline, primarily due to potential difficulties in raising adequate funding. Additionally, while the company has identified unmet needs in related angioedema conditions, there remains considerable uncertainty regarding the market viability of its lead product, deucrictibant. This combination of funding concerns and market uncertainties contributes to a negative outlook on Pharvaris's stock.

Pharvaris B.V. (PHVS) has been analyzed by 5 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 80% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 5 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.